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1 Introduction
The development of good medicines greatly 
contributes to improving QOL and reducing 
medica l costs by reducing the number of 
operations, shortening treatment time and 
hospital stays and lowering recurrence rates. 
According to WHO, there is no effective therapy 
for three-quarters of the world's diseases, and 
novel drugs need to be developed.  Meanwhile, 
the globalization of the pharmaceutical industry 
has set global standards for the efficacy, safety 
and quality of drugs.  To meet these standards, 
it is urgently necessary for Japan to strengthen 
its international competitiveness and improve its 
domestic environment for drug development.  By 
advancing our drug development technology and 
leading the worldwide pharmaceutical industry, 
Japan could compensate for its lack of natural 
resources with intellectual property, maintain 
independence from foreign companies in terms 
of medical supplies and safety assessments, 
and take the initiative in health and sanitation. 
Moreover, fostering human resources in the drug 
development area is an important task for an 
aging society, since senior citizens are the most 
frequent users of medicines.
2 Status and issues
 of drug development
2-1 Process of drug development
 — product development with high risk —
The first step in drug development is to screen 
a wide range of materials including naturally 
occur r ing organ ic compounds,  synthet ic 
products, biological materials and microbial 
metabol ites for pharmacolog ica l ly act ive 
substances and discover novel physiologically 
active substances with the potential to become 
medicine.  The properties, chemical structure 
and action mechanisms of the novel substance 
are then studied in detail.  These days, genome 
information is also utilized at this stage.  The 
initial stage takes two to three years.
In the next step, the substance screened in the 
previous step is subjected to non-clinical studies 
on its effectiveness (efficacy), safety (toxicity), 
pharmacokinetics (absorption, distribution, 
metabolism and excretion), stability, etc.  In 
safety evaluations, the substance is tested for 
acute, sub - acute and chronic toxicity and 
teratogenicity.  The non-clinical study stage takes 
from three to five years.
An investigational new drug that has passed 
non-clinical studies is then subjected to three 
stages of clinical trial: Phase I, performed on 
healthy, male subjects, Phase II, performed 
on a small number of patients, and Phase III, 
performed on a larger number of patients. 
C l i n ica l  t r i a l s  a re  conducted i n  med ica l  
institutions, adopting the double-blind test using 
pharmacologically inactive placebos.  The test 
results are statistically processed to assess the 
efficacy of the drug.  The clinical trial stage takes 
from three to seven years.
For  i nve s t i g a t ion a l  ne w d r ug s  who s e  
effectiveness, safety and quality have been approved 
through the above studies, the pharmaceutical 
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compa ny wi l l  subm it  an  appl icat ion for  
manufactur ing approval to the Ministry of 
Health, Labor and Welfare. Drugs that pass the 
examinations by Pharmaceuticals and Medical 
Devices Agency and the Pharmaceutical Affairs 
and Food Sanitation Council are approved as 
pharmaceutical products.  This approval stage 
takes one or two years.  In total, 10 to 17 years 
are required for drug development, and less than 
one per 11,000 drugs (data for Years 1998 to 2002 
provided by the 17 member companies of the 
Japan Pharmaceutical Manufacturers Association) 
qualifies at all these stages to become a product. 
Therefore, the development of pharmaceuticals 
involves a high risk (Figure 1)[1,2].
2-2 Drug development in Japan
 — Dependence of Japanese medicine
 on foreign products —
In Japan, drug development has been encouraged 
since the enforcement of the substance patent 
system in 1980[3].  Japan’s development capacity 
has increased with the expansion of the market, 
which gave birth to several world-class drugs 
in the 1990s.  As mentioned earl ier, drug 
development is very time-consuming and offers 
a low success rate, which is ref lected in the 
high research expenses; accounting for 8.6% of 
domestic drug sales revenue.
T h i s  propor t ion  i s  i ncompa r ably  h ig h  
compared to those in other manufacturing 
industries, being 2.5 times larger than the average 
(3.01%) for all industries.  The proportion is 
even higher than those in the communicatio
ns/electronics/electric measuring instrument 
(5.67%) and automobile (4.09%) industries, both 
of which spend large amounts on research and 
development (Figure 2).  The pharmaceutical 
industry has a 10% share of the total research 
expenses of all industries (data provided by 
the Statistics Bureau of the Ministry of Internal 
Affairs and Communications)[4].  Moreover, 
Figure 1 : Drug development process and success rates
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drug research expenses including development 
costs correspond to 13% of total drug sales.  The 
industry spends 23% of the research expenses 
on basic research, which is markedly higher 
compared to those in other industr ies (the 
average for all industries is 5.8%) (Table 1).
A large proportion of research expenses used 
by basic research reflects the peculiarity of the 
pharmaceutical industry in terms of patents. 
In the automobile and electr ical appliance 
industries, each product involves hundreds or 
thousands of patents.  Each patent has only minor 
inf luence, so existing patents rarely interfere 
with product development.  Meanwhile, in the 
pharmaceutical industry, only one basic patent 
exists for each product except for formulation 
patents.  To be approved as a new product, a drug 
must not be covered by an existing patent (Figure 
3).  In other words, a drug cannot be developed 
without conducting basic research, compelling 
Figure 2 : Proportion of research expenses to sales by industry (Year 2001)[2]
Source: “Survey of Research and Development” by the Ministry of Internal Affairs and Communications
Table 1 : Composition ratio of research expenses by industry and application (Year 2001)[2] (Unit: %)
Industry Basic research Applied research Development research
All industries                   5.8                 20.4                 73.9
Manufacturing industry                   5.7                 20.0                 74.3
Chemical industry                 15.7                 25.2                 59.1
General chemistry and chemical fibers                 10.7                 26.4                 62.9
Oils & fats and paints                   7.3                 25.7                 67.0
Pharmaceuticals                 23.0                 24.5                 52.6
Other chemical industries                   6.3                 24.6                 69.1
Electric machinery industry                   3.8                 19.2                 77.0
Electric machinery and apparatus                   5.2                 26.1                 68.6
Communications, electronics and electric measuring 
instruments
                  3.2                 16.6                 80.2
Automobiles                   1.9                 13.0                 85.1
Precision instrument industry                   1.8                 24.6                 73.6
Software industry                   1.3                   7.4                 91.3
Source: “Survey of Research and Development” by the Ministry of Internal Affairs and Communications
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the pharmaceutical industry to emphasize basic 
research.
Despite the efforts of domestic pharmaceutical 
manufacturers, who have spent a lot on research 
and perform all phases of clinical trials in Japan, 
to obtain manufacturing and marketing approval, 
domestic products constitute only 40% of the 
pharmaceuticals, with sales of 2 billion yen or 
more in the domestic market.  However, about 
60% of such domestic products have yet to 
be approved in the U.S., the U.K., Germany or 
France[6].  This demonstrates the vulnerability 
of Japan’s drug development technology where 
profit can only be made in the domestic market.
Under these circumstances, an agreement 
a t  T he  I nter nat iona l  Con ference  on the  
Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human 
Use ( ICH) (November 2000) has val idated 
applications for manufacturing approval in 
Japan based on non-clinical and clinical studies 
conducted overseas (adopted for applications 
submitted after July 1, 2003).  In response to the 
ICH agreement, the Pharmaceutical Affairs Law 
will be revised in April 2005.  Today, 11 out of 
31 drug products with global sales of 2 billion 
dollars or more are not marketed in Japan[7], but 
after this revision, foreign products including 
these 11 are likely to increase their share of the 
Japanese market[8].
Meanwhile, the Japanese pharmaceutical 
market makes up 12% (20% in fiscal year 1994) of 
the global market.  It is the second largest after 
the U.S. market, corresponding to the collective 
total of the German, French and British markets 
put together (Figure 4)[2].  In future, Japan will 
Figure 3 : Intellectual property rights for different products (schematic diagram)[5]
Figure 4 : Size of ethical drug markets in the world (Year 2001)[2]
Africa and Middle East
70(2.6%)
Asia-Pacific
190(7.0%)
Central and South America
130(4.9%)
Other European countries
240(8.9%)
U.K.
90(3.3%)
Italy
80(3.0%)
France
130(4.9%)
Germany
130(4.9%)
1,310(48.9%)
310(11.6%)
Total size of
the gloval
pharmaceutical
market
Source: GlaxoSmithkline Annual Report 2002
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be an important market and an arena for a hot 
technological race in the medical care industry.
Despite this large market (i.e. development 
opportunities), there is great concern that Japan 
will fall behind in the drug development area 
and become an “underdeveloped country” that 
only manufactures off -patent generic drugs. 
To avoid this, the government must emphasize 
drug development research and support human 
resource development in this area.
2-3 Gap between the new curriculum for
 pharmaceutical departments and universities
 (hereafter, represented as pharmaceutical
 universities) and human resource
 development in the drug development area
To date, Japanese pharmaceutical manufacturers 
h a v e  m a i n l y  a s s i g n e d  g r a d u a t e s  f r o m  
pharmaceutical universities to drug development. 
As mentioned above, basic research constitutes 
a significant proportion of drug development 
(Table 1), so fostering superior human resources 
engaged in basic research i s  essent ia l  to 
medicinal science.  Meanwhile, the six-year 
program for pharmaceutical universities, which 
will be implemented in 2006, aims to educate 
professionals in patient compliance instruction, 
medicat ion h istor y management and r i sk 
management for drug-induced suffering[9]. From 
an international viewpoint, six-year educational 
programs to qualify as a pharmacist predominate 
over four-year programs, so in this sense, Japan 
should have introduced the six-year programs 
much earl ier [10].   The new curr iculum for 
pharmaceutical education in Japan will emphasize 
clinical pharmacy rather than basic research. 
“The Model Core Curriculum for Pharmaceutical 
Education,” announced by the Pharmaceutical 
Society of Japan in August 2002[11], devotes only 
four pages to “The Development and Production 
of Pharmaceuticals”; corresponding to only 
one - third of the pages (14 pages) devoted to 
“Practices of Pharmacists in Hospitals and 
Pharmacies” (Table 2).
In addition, there are some defenses of the 
coexistence*1 of six-year programs and the 
“four (undergraduate) plus two (graduate)”
-year programs that have been approved as an 
interim measure for the next twelve years.  This 
suggestion is justified by negative opinions*2 and 
concerns about the transition into the six-year 
programs.  Moreover, if a university shifts into 
a six-year program with its current number of 
students, the number of teaching staff would be 
twice that currently required, of which one-sixth 
must have at least 5 years of working (clinical) 
experience.  Therefore, the coexistence of 
the two programs is also supported by school 
administrators who do not wish the number of 
teaching staff to increase.
Nevertheless, the aim of pharmaceutical education 
reform is not to improve Japan’s international 
competitiveness in the drug development area. 
Thus, it is likely that fostering “drug development 
professionals” will be even more difficult in Japan 
over the next twelve years.
Table 2 : Contents of the core curriculum for pharmaceutical education and number of pages devoted to each of them
Core curriculum for pharmaceutical education Number of pages
Professional pharmaceutical education
Studying physical pharmacy 7
Studying chemical pharmacy 9
Studying biological pharmacy 11
Health and environment 5
Medicines and Diseases 13
Drug development Formulation 2
Drug development and manufacturing 4
Pharmacy and Society 3
Practical on-site training Hospital and pharmacy pharmacists 14
Graduation training Problem solving 2
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3 Drug development
 in the U.S.[12,13]
The level of a country’s drug development 
technology can be inferred from the sales of 
domestic pharmaceutical manufacturers in the 
global market.  Japan has the second largest 
pharmaceutical market in the world, and the 
Japanese pharmaceutical industry shares fourth 
place with France in terms of total sales, followed 
by Germany by a narrow margin (Figure 5)[5,7].
C o m p a r i n g  s a l e s  a m o n g  i n d i v i d u a l  
pharmaceutical manufacturers in the world 
(Figure 6), U.S. and European companies head the 
list.  Takeda Chemical Industries, Ltd. ranks 15th; 
the highest of the Japanese companies.  Of the 
top 14 companies, seven are from the U.S.; each 
of these companies has three or four world-class 
products[6], which allows them to recover R&D 
expenses and ensures the availability of budget 
for development for the next generation.
The fact that both the domestic and foreign 
pharmaceut ica l  industr ies spend f rom 10 
to 20 % of their sa les revenue on research 
and development (Table 3) suggests a close 
correlation between the amounts of sales and 
R&D expenses respectively; thus, the level of 
drug development research could be raised by 
increasing sales.  However, a closer look at life 
science policies reveals that the U.S. could not 
have established such a strong drug development 
capability just by creating megacorporations 
through mergers in the 1990s (Figure 6)[12,13].
The life science research budget of the U.S. 
government is divided among the National 
Institutes of Health (NIH), The National Science 
Foundation (NSF) and the Department of Energy 
(DOE).  NIH (27 bil l ion dollars per year) is 
allocated 95% or more of the total life science 
research budget, of which 80% is provided to 
other institutions as “NIH grants,” “research 
contracts” and “cooperat ive agreements.” 
Ninety-percent of these grants are allocated to 
universities and other non-profit organizations, 
Figure 5 :  Sales shares of top 31 companies with sales
 of 2 billion dollars or more by country[5,7]
Figure 6 : Ranking of major pharmaceutical manufacturers of the world by sales and reorganization of the industry[6]
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which is an exceptionally high proportion of 
the total R&D budget, of which 46% is allocated 
to industries and only 34% to universities.  NIH 
recognizes that basic research constitutes a 
significant area in li fe science, i.e. the area 
engaged in the development of pharmaceuticals 
and therapies.  The institute considers that raising 
the level of basic research in domestic universities 
and making them introduce pharmaceutical seeds 
to companies will improve the developmental 
c a p a c i t y  o f  d o m e s t i c  p h a r m a c e u t i c a l  
manufacturers[12].  In fact, the NIH research 
budget has supported 40% (43 out of 107) of the 
novel active ingredients that have been marketed 
from 1998 through 2000.
In addition, NIH internally conducts research 
activities using 15% of its research budget, 
employing 2,000 researchers with MDs and 
2,800 with PhDs in other areas of natural 
science.  This shows that the institutes’ policy, 
which emphasizes basic research, has been 
conserved since its foundation.  The results of 
the basic research are reflected in the clinical 
practice of providing the best therapies (and 
pharmaceutica ls) to pat ients ; meanwhi le, 
information gathered through clinical practice 
is fed back to the basic research.  This approach 
has worked effectively, and NIH has produced 112 
Nobel Prize winners (in Medicine and Chemistry) 
since its foundation in 1935.
This shows that successful pharmaceutical 
(drug) development is a product of policies 
promoting basic research in life science.
In addition, NIH has contributed to technology 
transfer and the clinical development of new 
drugs by al locating a budget to technology 
transfer programs such as the Bayh Dole Act, 
CRADA (Cooperative Research and Development 
Agreement) and SBIR/STTR.
The Bayh Dole Act has enabled universities 
to retain the title to inventions made under NIH 
(government) - funded research programs.  It 
led to the development of drugs such as Epogen 
and Procrit, both of which were discovered 
in Columbia University through NIH - funded 
research programs and were commercialized by 
Amgen, Ltd. and Johnson & Johnson, respectively. 
Each of these products had annual sales of 500 
million dollars in 2000.
C R A DA  i s  a  s y s t e m  i n v o l v i n g  d i r e c t  
Table 3 : Proportion of R&D expenses to sales of major pharmaceutical manufacturers of the world (Year 1999)[6]
Ranking Company name R&D expenses (million dollars) Proportion of sales (%)
1 Pfizer Inc. (U.S.)                   4,036                 14.7
2 Aventis (France)                   3,228                 16.4
3 AstraZeneca (U.K.)                   2,923                 15.8
4 Novartis AG (Switzerland)                   2,831                 13.1
5 Johnson & Johnson (U.S.)                   2,600                   9.5
6 Roche Diagnostics K.K. (Switzerland)                   2,521                 13.7
7 Merck & Co., Ltd. (U.S.)                   2,068                   6.3
8 Glaxo Wellcome (U.K.)                   2,056                 14.9
9 Bayer AG (Germany)                   2,001                   7.8
10 Bristol-Myers Squibb (U.S.)                   1,843                   9.1
11 Eli Lilly and Company (U.S.)                   1,784                 17.8
12 American Home Products (U.S.)                   1,740                 12.8
13 SmithKline Beecham (U.K.)                   1,649                 12.1
14 Pharmacia & Upjohn Inc. (U.S.)                   1,434                 19.8
15 Abbott Laboratories  (U.S.)                   1,194                   9.1
16 Schering-Plough K.K. (U.S.)                   1,191                 13.0
17 Sanofi-Synthelabo Inc.  (France)                      851                 17.0 
                 Takeda Pharmaceutical Co., Ltd. (Japan)                      692                   8.4 
                 Sankyo Co., Ltd. (Japan)                      578                 10.9 
Source: “Pharmaceutical Affairs Handbook 2001” by Jiho, Inc.
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collaboration between NIH and profit-oriented 
organizations.  CR ADA grants the par tner 
corporation the option of acquiring an exclusive 
l icense to any invent ion made under the 
cooperative research.  NIH seems to fulfill its 
missions by supporting research that can return 
profit to society through commercialization, 
rather than by acqui r ing l icense income. 
Moreover, the research results achieved under 
CRADA for cl inical development represent 
high-quality data and can be used when applying 
for FDA approval.  CRADA has contributed to the 
development of products such as Taxol, Glivec 
and Endostatin, which are molecular- targeted 
drugs with excellent efficacy in cancer therapy.
SBIR/STTR support venture capital companies 
in promoting the discovery of pharmaceutical 
seeds.  Since it takes a long time (from 10 to 
17 years) before a seed becomes a product and 
brings profits, NIH grants are attractive to venture 
capital companies with limited funding, despite 
the high competition rate.  Moreover, the tough 
competition for the grants indirectly benefits the 
winners, e.g. by raising their stock prices.
Together with the research budget, the 
technology transfer budget of NIH has created an 
environment in which universities, companies 
and venture capital companies can participate in 
drug development (Figure 7)[12]. 
As can be seen, the f lows of funds, human 
resources and information in the U.S. drug 
development are different from those in Japan. 
In Japan, most competitive funds are allocated 
to universities, and vir tual ly none to drug 
development in companies. Commercialized 
drugs developed under government- funded 
programs are substantially limited to orphan 
drugs (drugs for intractable diseases with 
few patients).  Companies have individually 
developed human resources and have managed 
information concerning drug development, from 
the discovery of pharmaceutical seeds to their 
commercialization.  Venture capital companies 
dedicated to pharmaceutical seed discovery have 
not been nurtured.  As can be seen, the drug 
development environment in Japan is in marked 
contrast with that in the U.S..
As mentioned above, U.S. universities are 
supported by the government in launching 
many pharmaceutical seeds.  The success of the 
system can also be attributed to the educational 
systems and human resource recru itment 
in pharmaceutical universities and graduate 
schools.  As explained earlier, the United States 
basically adopts six-year educational programs 
for the pharmaceutical universities as in other 
developed countries, but many universities allow 
their students the option of graduating in four 
years to receive a bachelor's degree (BS).  As a 
consequence, many students who have studied 
for four years in pharmaceutical universities 
take doctoral courses in other graduate schools 
Figure 7 : Innovation cycle in U.S. life science research[12]
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(Figure 8)[14].
This personnel exchange is also seen among 
teaching staff; since professors from science and 
technology departments are often employed as 
faculty members of pharmaceutical departments, 
and vice versa.  Moreover, faculty members 
are al lowed to serve concurrently in both 
departments.  In this environment, they can share 
academic interests to expand mutual academic 
areas, dramatically increasing the opportunities 
for pharmaceutical seed discovery[15].
4 World-class pharmaceuticals
 developed by
 Japanese manufacturers
In the global pharmaceutical market, 31 
products have annual sales of 2 billion dollars or 
more; most of them are drugs for chronic diseases 
including antihyperl ipidemic agents (statin 
agents), antiulcer agents (proton pump inhibitors) 
and ant idepressants  (select ive seroton in 
reuptake inhibitors, serotonin and noradrenaline 
reuptake inhibitors). Among them, three are 
original Japanese products: the antiulcer agent 
“lansoprazole” from Takeda Pharmaceutical Co., 
Ltd., the antihyperlipidemic agent “pravastatin” 
from Sankyo Co., Ltd. and the therapeutic agent 
for prostatic hyperplasia “tamsulosin” from 
Yamanouchi Pharmaceutical Co., Ltd.  In addition, 
seven more Japanese products are listed among 
products with annual sales of 1 billion dollars or 
more (Table 4)[7]. 
So far, the vulnerability of Japanese drug 
development capability has been emphasized. 
However, antihyperlipidemic agents, which 
are original Japanese products, have top global 
sales by therapeutic category.  These products 
were developed utilizing Japanese fermentation 
tech nolog y,  wh ich  ga i ned  i nte r nat iona l  
recognition in 1970-1990s.
These drugs are cal led statin agents and 
reduce blood cholesterol levels by inhibiting 
cholesterol biosynthesis.  Their sales have grown 
in proportion to the spread of lifestyle -related 
diseases.
T h e  d e ve l o p m e nt a l  p r o c e s s  o f  t h e s e  
drugs has important clues essential to drug 
development.  It is introduced here as an 
example for those discussing guidelines for 
human resource development in the area of drug 
development[16,17].
Research into statin agents started in the 1960s 
following a suggestion by Dr. Hamao Umezawa. 
The discoverer of kanamycin (an antibiotic) 
suggested that “screening microbial products 
for enzyme inhibitors should lead to drug 
discovery.”  Numerous microbial products were 
screened, and in 1973, a substance (compactin) 
that specifically inhibits HMG-CoA reductase, 
a rate - determining enzyme in cholesterol 
biosynthesis, was discovered in a metabolite of 
Penicillium citrinum (green mold found on rice 
grains produced in Kyoto).  However, compactin 
d id not lower blood cholesterol levels in 
pharmacological in vivo tests using rats, and the 
research was abandoned for more than two years. 
Then, another research group, about to slaughter 
their old experimental chickens, heard about 
this situation and provided their chickens for an 
in vivo test.  The dramatic effects of compactin 
obser ved in the ch ickens conv inced the 
researchers to continue their research.  Moreover, 
administration of the compound to dogs led 
Figure 8 : Career options for senior students in pharmacy departments in U.S. universities
University of Mississippi (1999) as an example
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to the discovery of another substance-inhibiting 
cholesterol biosynthesis from their urine.  This 
substance, which was more effective and less toxic 
than compactin, was later approved as a product 
(pravastatin).  For commercial production, a 
two-step fermentation method has been adopted, 
where compactin produced by P. citrinum is 
converted into pravastatin by an Australian soil 
actynomycetes, Streptomyces carbophilius.
The development of pravastatin was essential 
in arteriosclerosis research.  Using the pravastatin 
precursor, compactin, Goldstein and Brown 
revealed the regulation mechanism of cholesterol 
metabolism and won the Nobel Prize for Medicine 
in 1985.
The success of pravastatin development can 
be attributed to the organic linkage of each stage 
listed in the previous page (Figure 9).
Interest ing ly,  a  Br it i sh pharmaceut ica l  
manufacturer (Beecham Group, Plc.) isolated 
compactin from P. brevicompactum around the 
same time as Sankyo Group, but could find only 
weak antifungal activity.  This is a good example 
of the big difference between the discovery of a 
new compound and the development of a new 
drug.
5 Pharmaceuticals developed
 through university research
In the guidance brochure “For students who 
start to study pharmaceutical sciences,” The 
Pharmaceutical Society of Japan claims that 
pharmaceutical science is an academic area based 
on chemistry, biology and physics and that its 
mission is to contribute to “drug-development 
chemistry,” “cl inical pharmacy,” “hygienic 
pharmacy” and “life science”[18].
Despite this consensus, “drug development 
(chemistry)” has been left to pharmaceutical 
manufacturers, while pharmaceutical chemistry 
taught in universities has mainly focused on 
teaching organic chemistry to develop novel 
synthetic methods.  Thus, compared to the 
U.S., only few pharmaceutical seeds have been 
discovered in Japanese university laboratories. 
However, since the foundation of this area, 
Japanese researchers have conducted extensive 
research on the active ingredients of medicinal 
plants or crude drugs.  This research has 
contr ibuted to the development of cer tain 
products, two of which are introduced as 
Table 4 : Original Japanese products (for 2001: 1 billion dollars or more)[7]
Manufacturer Ingredient Efficacy
Takeda Pharmaceutical Co., Ltd. lansoprazole anti-ulcer PPI
Sankyo Co., Ltd. pravastatin antihyperlipidemic statin
Yamanouchi Pharmaceutical Co., Ltd. tamsulosin prostatic hyperplasia
Takeda Pharmaceutical Co., Ltd. leuproreline acetate prostatic cancer, etc.
Daiichi Pharmaceutical Co., Ltd. levofloxacin antibiotics
Takeda Pharmaceutical Co., Ltd. pioglitazone type II diabetes
Taisho Pharmaceutical Co., Ltd. clarithromycin antibiotics
Takeda Pharmaceutical Co., Ltd. candesartan antihypertensive AIIRB
Eisai Co., Ltd. rabeprazole anti-ulcer PPI
Eisai Co., Ltd. donepezil Alzheimer's disease
Figure 9 : Key points in the development of pravastatin (therapeutic agent for hypercholesterolemia)
1) Discovery of the active substance ⇒ Discovery of compactin, an HMG-CoA reductase inhibitor
2) In vivo pharmacological evaluation ⇒ No effect observed in rats, efficacy observed in chickens
3) Resolution of drug kinetics ⇒
Discovery of a highly active, low toxicity substance from the urine of 
compactin-administered dogs
4) Establishment of a large-scale synthetic method ⇒ Establishment of a two-step fermentation method
5) Safety and toxicity evaluations ⇒ Toxicity assessment of compactin, safety assessment of pravastatin
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examples.
The f irst example is ir inotecan, a typical 
university-launched drug that has been approved 
in more than 100 countries.  This anticancer drug 
was developed through joint research between 
Tadashi Miyasaka, a professor emeritus at Showa 
University, and a company (Yakult Honsha Co., 
Ltd.) and has annual sales of 900 million dollars 
(2003)[19].
Irinotecan was produced through the chemical 
modification of a substance called camptothecin, 
which had been isolated from the Chinese tree 
Camptotheca acuminata. Camptothecin inhibits 
the propagation of experimentally transplanted 
tumors, but its use as a medicine was once 
abandoned due to its severe side effects including 
myelosuppression and hemorrhagic cystitis. 
Miyasaka focused on a trace component (Figure 
10, the compound shown on the left in which R 
= OH) isolated from the same plant, which was 
structurally similar to camptothecin but had 
lower toxicity, and produced many derivatives 
of this naturally occurring substance.  After 
individually assessing their antitumor activities, 
he finally reached irinotecan, which had few 
side effects, sufficient solubility in water for 
intravenous administration and a long half- life 
time in plasma (Figure 10).  Later, it was found 
out that irinotecan is a completely new type of 
drug that acts by inhibiting DNA topoisomerase 
I.  In 1994, the substance was approved as a 
drug for lung, ovarian and cervical cancers and 
was released by Yakult Honsha Co., Ltd., which 
mainly cooperated in evaluating the drug efficacy. 
In 1995, it received approval for additional 
indications including stomach, colon and rectal 
cancers and recurrent breast cancer.  Today, this 
drug is the first choice for treating rectal cancer 
in the U.S. and European countries.
Another example is an investigational drug 
named FTY720, which is an immunosuppressant 
developed by Tetsuro Fujita, a professor emeritus 
at Kyoto University.  The drug was developed 
from myriocin, which had been isolated from 
Chinese caterpillar fungus which is traditionally 
used in Chinese medicine[20].
In studying the components of Trichoderma 
polysporum that damage shiitake mushrooms, 
Fujita noticed that this fungus had the same 
name a s  that  of  a  f u ngus  produci ng the 
immunosuppressant, cyclosporin A*3. He also 
found out that a peptide analogue he had 
isolated from this fungus had been reported as a 
component of Chinese caterpillar fungus, so he 
examined the components of Chinese caterpillar 
fungus and discovered myriocin.  As well as 
assessing the immunosuppressive activity, he 
worked with researchers of Taito Co., Ltd. and 
Yoshitomi Pharmaceutical Industries, Ltd. (the 
current Mitsubishi Pharma Corp.) to simplify its 
chemical structure, and he synthesized FTY720 
(Figure 11).
Using FTY720 as an immunosuppressant in 
organ transplantation is currently being studied 
overseas by Novartis Pharma Co., Ltd.  The drug is 
also expected to serve as an investigational drug 
Figure 10 : Structural formulas of camptothecin and irinotecan
Figure 11 : Structural analogy between myriocin and FTY720
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to treat autoimmune diseases.
These examples suggest that, of or iginal 
Japanese pharmaceuticals, those accepted 
international ly have been developed from 
seeds discovered in areas such as fermentation 
technology, natural products chemistry and 
organic synthesis, which are specialties of 
Japan[21].  This suggestion is supported by the 
following data.  In the past decade or so, drugs 
have been developed through combinatorial 
chemistry; however, a recent report shows that 
naturally occurring substances have physical 
proper ty distr ibutions simi lar to those of 
pharmaceuticals, while products of combinatorial 
chemistry are less diverse and have physical 
property distributions dissimilar to those of 
pharmaceuticals (Figure 12)[22].
6 The necessity of establishing
 a new educational system
 for fostering human resources
 in the drug development area
 (Suggestion)
S o  f a r,  t h i s  a r t i c l e  h a s  r e v i e we d  t he  
technological status of drug development in Japan 
and the fostering of human resources who would 
be engaged in this area[24].  By 2010, the number 
of domestic pharmaceutical manufacturers will 
decrease to between 3 and 5 companies.  Japan’s 
current level of drug-development technology 
does not match that in U.S. and European 
countries, so Japan must open to meet global 
standards in the pharmaceutical industry.
Meanwhile, Japan has ten original products 
with annual global sales of 1 billion dollars (Table 
4).  There are some university-launched products 
that have been accepted internationally. This 
suggests that, although currently vulnerable, 
Japan's drug-development technology has the 
potential to improvement[25].  Although there 
are certain other unsolved issues such as the 
reforming of public consciousness towards 
clinical trials, it is urgently necessary to take 
advantage of the implementation of six-year 
programs for pharmaceutical education in 2006 
to establish a new educational environment 
focusing on the fostering of drug development 
professionals.
To date, there are about 18,000 researchers 
working for pharmaceutical manufacturers 
(announced by Ministry of Health, Labor and 
Welfare)[5], which is about half that in the U.S. on 
a population basis.  Assuming that the average 
working life of a researcher is about 20 years 
(ages 25 through 45), we must educate an average 
of at least 900 researchers per year in the drug 
development area.  This means that we would 
need at least 1,500 new researchers per year to 
match the U.S.
According to the pharmaceutical manufacturers, 
Japan is currently lacking those who “can 
synthesize organic compounds,” “can handle 
(not only microorganisms and cells but also) 
animals” and “are strong in biostatistics.”  The 
first two categories are accompanied by “dirty, 
dangerous and demanding” jobs, which should 
be avoided by young people.  In addition, 
pharmaceut ica l  g raduates prefer work at  
hospitals and pharmacies to work involving drug 
development.  Consequently, pharmaceutical 
manufacturers recruit students from life science 
departments, providing biotechnology-oriented 
educat ion, but these depar tments do not 
provide sufficient lectures or training sessions 
on “organic synthesis” and “animal handling” in 
their curricula.  Thus, these departments cannot 
educate the human resources truly required by 
pharmaceutical manufacturers.
As intel lectual property, pharmaceutical 
Figure 12 : Comparison of physical property distributions among pharmaceuticals, naturally occurring substances
 and products of combinatorial chemistry[22, 23]
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products are protected by four types of patent, 
i .e.  “substance patent”,  “process patent”,  
“usage patent” and “formulation patent”.  Thus, 
drug development exploits novel substances 
(compou nd s) ,  m a nu fac t u r i ng  proces se s  
(synthetic processes), usage (pharmacological 
effects/efficacy) and preparations (formulations). 
To be approved as pharmaceuticals, their safety 
must be confirmed through non- clinical and 
clinical studies.  From these aspects, establishing 
a completely new system (departments) is 
suggested for intensive education in the following 
five subjects:
(1)  Chemical and biological foundations for 
developing novel pharmaceutical seeds 
(compounds)
(2)  Chemical and biological methods for 
manufacturing novel pharmaceuticals
(3)  Pharmacology for discovering novel effects 
and the efficacy of pharmaceuticals
(4)  Pharmaceutics and pharmacokinetics 
for exploring novel DDSs (drug delivery 
systems) suitable for individual drugs
(5) Toxicology for assessing safety and toxicity
Here, the “new system” does not refer to 
the “four plus two”-year courses that will be 
establ ished in many universit ies based on 
their existing curricula; instead, it refers to 
an educational/research environment capable 
of providing human resources, patents and 
information directly to the pharmaceutical 
industry.
The first two subjects in the above list would 
foster those who “can synthesize organic 
compounds,” and the latter three would foster 
those who “can handle an imals” and “are 
strong in biostatistics.” Furthermore, growing 
expectations of genome analysis outcomes 
forecast  the protect ion of  “ the usage of  
genome-based pharmaceuticals” as intellectual 
property.  Considering this future trend, we 
should also add bioinformatics to the above 
list as well as conventional molecular biology. 
Bioinformatics is essential to all the subjects in 
the list, but Japan lags behind other countries in 
this area.
7 Conclusions
Pharmaceuticals are life science-based products 
with the highest added value.  From research, 
and development through manufacturing and 
marketing, they are produced under str ict 
regulations including GLP (Good Laboratory 
Practice), GCP (Good Clinical Practice), GMP 
(Good Manufacturing Practice) and GPMSP 
(Good Post-Marketing Surveillance Practice). 
They require higher R&D expenses and longer 
R&D periods compared to those for products 
of other industries.  Therefore, the equation 
that “drug development technology = search for 
novel bioactive substances + biotechnology” is 
insufficient for developing excellent drugs.
The University of Tokyo, Kyoto University and 
Kitasato University have established a program 
for educating experts in clinical trials, which are 
required for commercializing pharmaceuticals 
(Nihon Keizai Shimbun issued on December 6, 
2004).  The program is expected to improve the 
level and efficiency of clinical trials as well as 
the level of evaluating new drugs for approval. 
If we can take advantage of this program to 
improve the environment surrounding the drug 
development process, from pharmaceutical 
seed discovery through investigational drug 
development, Japan could achieve a remarkable 
breakthrough in its drug development technology 
and develop world-class pharmaceuticals.  After 
the introduction of the six-year programs in 
April 2006, pharmaceutical education, which 
has fostered both “pharmaceutical manufacturer 
personnel” and “pharmacists,” wil l lose its 
balance and greatly lean towards “pharmacist 
education.”  This wil l make foster ing drug 
development professionals even more difficult.
Therefore, we should leave the education 
o f  p h a r m a c i s t s  a s  m e d i c a l  wo r ke r s  t o  
pharmaceutical universities shifting into the 
six-year program, and establish a completely new 
educational system (university departments etc.) 
that can directly provide human resources, seeds 
and information to the pharmaceutical industry 
to protect Japan’s “drug development technology 
as intellectual property” and “health in an aging 
society.”
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Notes
*1 In the first twelve years from 2006, those 
who have finished “four (undergraduate) 
plus two (graduate)”- year educational 
programs in pharmaceutical universities 
and have further taken clinical pharmacy 
courses and practical training at hospitals 
or pharmacies, which are required for 
graduating from six-year courses, will be 
qualified to take the National Examination 
for Pharmacists.  Thereafter, however, those 
who have finished the “four (undergraduate) 
plus two (graduate)”- year educational 
programs will not be qualified to take the 
National Examination.  In other words, 
special exemptions would apply to those 
who have finished the two-year courses in 
graduate schools in the first twelve years 
from 2006.
*2 The expression “negative opinions” may be 
misleading, but since the government has 
legislated “the qualifying of pharmacists 
= six-year education in pharmaceutical 
science departments = improved quality of 
pharmacists,” “human resource development 
in the drug development area” should be 
clearly separated from “the licensing of 
pharmacists.”  Many authorities concerned 
claim that “four-year educational programs 
are necessary for providing diverse career 
options for graduates f rom pharmacy 
col leges,” but these hal fway measures 
discussed in *1 will not lead to “successful 
human resource development in the drug 
development area.”  Refer to lines 5 -7 on 
p.144 and lines 2-7 on p.145 in the above 
reference[10].
*3 It was later found that the fungus belonged 
to Tolypocladium inflatum.
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